
Sign up to save your podcasts
Or


Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
By STAT4.5
320320 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.

1,993 Listeners

756 Listeners

1,105 Listeners

818 Listeners

498 Listeners

125 Listeners

6,097 Listeners

61 Listeners

85 Listeners

34 Listeners

5,576 Listeners

55 Listeners

21 Listeners

403 Listeners

17 Listeners

11 Listeners